BRIACELL THERAPEUTICS CORP. Operating Expenses
BRIACELL THERAPEUTICS CORP. (BCTX) reported Operating Expenses of $7.62 million for the 3-month period ending 2026-04-30, per its 10-Q filed 2026-06-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-06-09
- BRIACELL THERAPEUTICS CORP. operating expenses for the quarter ending 2026-04-30 was $7.62M, a 20.42% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. operating expenses for the quarter ending 2026-01-31 was $7.53M, a 5.05% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. operating expenses for the quarter ending 2025-10-31 was $8.32M, a 61.52% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. operating expenses for the quarter ending 2025-07-31 was $8.55M, a 48.31% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. operating expenses for fiscal 2025 was $27.20M, a 18.38% decline from fiscal 2024.
- BRIACELL THERAPEUTICS CORP. operating expenses for fiscal 2024 was $33.33M, a 43.22% increase from fiscal 2023.
- BRIACELL THERAPEUTICS CORP. operating expenses for fiscal 2023 was $23.27M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-04-30 | $7.62M 10-Q · filed 2026-06-09 | $15.15M derived: sum of 2 quarters · filed 2026-06-09 | $23.48M 10-Q · filed 2026-06-09 | $32.03M derived: sum of 4 quarters · filed 2026-06-09 |
| 2026-01-31 | $7.53M 10-Q · filed 2026-03-10 | $15.85M 10-Q · filed 2026-03-10 | $24.41M derived: sum of 3 quarters · filed 2026-03-10 | $30.74M derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-10-31 | $8.32M 10-Q · filed 2025-12-11 | $16.88M derived: sum of 2 quarters · filed 2025-12-11 | $23.21M derived: sum of 3 quarters · filed 2026-06-09 | $30.37M derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-07-31 | $8.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | $14.88M derived: sum of 2 quarters · filed 2026-06-09 | $22.05M derived: sum of 3 quarters · filed 2026-06-09 | $27.20M 10-K · filed 2025-10-16 |
| 2025-04-30 | $6.33M 10-Q · filed 2026-06-09 | $13.50M derived: sum of 2 quarters · filed 2026-06-09 | $18.65M 10-Q · filed 2026-06-09 | $24.42M derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-01-31 | $7.17M 10-Q · filed 2026-03-10 | $12.32M 10-Q · filed 2026-03-10 | $18.09M derived: sum of 3 quarters · filed 2026-03-10 | $27.32M derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-10-31 | $5.15M 10-Q · filed 2025-12-11 | $10.92M derived: sum of 2 quarters · filed 2025-12-11 | $20.15M derived: sum of 3 quarters · filed 2025-12-11 | $29.98M derived: sum of 4 quarters · filed 2025-12-11 |
| 2024-07-31 | $5.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | $15.00M derived: sum of 2 quarters · filed 2025-10-16 | $24.83M derived: sum of 3 quarters · filed 2025-10-16 | $33.33M 10-K · filed 2025-10-16 |
| 2024-04-30 | $9.23M 10-Q · filed 2025-06-16 | $19.06M derived: sum of 2 quarters · filed 2025-06-16 | $27.56M 10-Q · filed 2025-06-16 | $35.27M derived: sum of 4 quarters · filed 2025-06-16 |
| 2024-01-31 | $9.83M 10-Q · filed 2025-03-12 | $18.33M 10-Q · filed 2025-03-12 | $26.04M derived: sum of 3 quarters · filed 2025-03-12 | $31.72M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-10-31 | $8.50M 10-Q · filed 2024-12-16 | $16.21M derived: sum of 2 quarters · filed 2024-12-16 | $21.89M derived: sum of 3 quarters · filed 2024-12-16 | $26.37M derived: sum of 4 quarters · filed 2024-12-16 |
| 2023-07-31 | $7.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-10-29 | $13.38M derived: sum of 2 quarters · filed 2024-10-29 | $17.87M derived: sum of 3 quarters · filed 2024-10-29 | $23.27M 10-K · filed 2024-10-29 |
| 2023-04-30 | $5.68M 10-Q · filed 2024-06-14 | $10.16M derived: sum of 2 quarters · filed 2024-06-14 | $15.57M 10-Q · filed 2024-06-14 | |
| 2023-01-31 | $4.49M 10-Q · filed 2024-03-18 | $9.89M 10-Q · filed 2024-03-18 | ||
| 2022-10-31 | $5.40M 10-Q · filed 2023-12-14 | |||
| 2022-04-30 | $4.12M 10-Q · filed 2023-06-14 | $7.77M derived: sum of 2 quarters · filed 2023-06-14 | $10.05M 10-Q · filed 2023-06-14 | |
| 2022-01-31 | $3.65M 10-Q · filed 2023-03-16 | $5.93M 10-Q · filed 2023-03-16 | ||
| 2021-10-31 | $2.28M 10-Q · filed 2022-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |